SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is experiencing a surge in trading volume and investor interest driven by unconfirmed market rumors regarding a potential acquisition by a large-cap biopharmaceutical company. The community remains divided, with long-term holders eyeing a potential buyout premium while others caution that the lack of official confirmation from the company or major outlets suggests the price action may be speculative volatility.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors react to its recent NYSE debut and the significant premium currently trading above its net asset value. The community is actively debating the impact of a six-month share lockup on the float, with many speculating on the fund's potential for future volatility driven by its exposure to high-profile private AI companies like Anthropic, SpaceX, and OpenAI.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as a highly speculative meme coin, drawing intense division between traders gambling on its volatility and those warning of a potential pump-and-dump scheme. The community remains polarized, with some observing chart patterns and accumulation while others caution that the asset lacks utility and exhibits significant concentration among top holders.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is generating significant buzz as investors weigh upcoming earnings reports against expectations for a major NASA Lunar Terrain Vehicle (LTV) contract award. The community remains deeply divided, with bulls pointing to strong forward revenue guidance and long-term space infrastructure growth, while bears emphasize execution risks and the volatility associated with contract timing.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing significant price volatility following a post-earnings sell-off, triggering intense debate among investors over whether this is a technical gap-fill, temporary market noise, or a broader conspiracy regarding a potential low-cost acquisition by its distribution partner. While many in the community remain bullish on the brand's long-term growth and dominant shelf presence, others are actively expressing frustration with management and speculative concerns about corporate strategy.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly Inc. is experiencing intense volatility and community debate as traders grapple with a sharp post-earnings rally, heavy insider selling, and high short interest. While bulls highlight potential for long-term growth driven by AI and edge computing, bears argue the valuation is detached from fundamentals, leading to frequent clashes over technical resistance levels and short-squeeze potential.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is currently trending as investors react to a new shelf registration filing, sparking debate about potential financial stress versus strategic capital management. The community remains deeply divided, with some traders actively betting on a bullish breakout toward key resistance levels, while others highlight concerns over regulatory pressures, margin compression, and persistent downward price action.

Apollo Global Management, Inc. provides asset management services. It offers its clients excess return at every point along the risk-reward spectrum from investment grade to private equity with a focus on three business strategies: yield, hybrid, and equity. It operates through following segments: Asset Management, Retirement Services and Principal Investing. The Asset Management segment focuses on credit and equity investing strategies. The Retirement Services and Principal Investing segment consists of realized performance fee income, realized investment income from balance sheet investments, and certain allocable expenses related to corporate functions supporting the entire company. The company was founded by Marc Rowan in 1990 and is headquartered in New York, NY.

Apollo Global Management Inc

Apollo Global Management is currently the subject of intense investor discussion as it balances strong asset growth with sector-wide anxiety regarding private credit liquidity. While the company is actively expanding its digital infrastructure and sports investment footprint, market participants remain closely divided between those viewing the stock as a resilient value opportunity and others concerned about the potential for broader credit market contagion.

CBIZ, Inc. is a professional services advisor to middle market businesses and organizations nationwide. It offers its services in accounting, tax, advisory, benefits, insurance, and technology. The firm delivers forward-thinking insights and actionable solutions to help clients anticipate what's next and discover new ways to accelerate growth. It operates through the following segments: Financial Services, Benefits and Insurance Services and National Practices. The Financial Services segment offers accounting, tax, government health care consulting, financial advisory, valuation, and risk advisory services. The Benefits and Insurance Services segment includes group health benefits consulting, property and casualty brokerage, retirement plan services, and payroll. The National Practices segment deals with managed networking and hardware, and healthcare consulting. The company was founded by Michael G. DeGroote Sr. in 1987 and is headquartered in Independence, OH.

Cbiz Inc

Investors are actively debating the long-term outlook for CBIZ as the firm navigates integration challenges following major mergers. Discussions highlight concerns over recent financial performance and debt levels, while the community remains divided between those viewing the current valuation as an oversold opportunity and others wary of ongoing corporate headwinds.

The Estée Lauder Companies, Inc. engages in the manufacture of skin care, makeup, fragrance and hair care products. It sells products under Estée Lauder, Clinique, Origins, MAC, Bobbi Brown, La Mer, Jo Malone London, Aveda and Too Faced. The company was founded by Estee Lauder and Joseph Lauder in 1946 and is headquartered in New York, NY.

Estee Lauder Cos., Inc. - Ordinary Shares - Class A

Estee Lauder Cos. Inc

Estee Lauder is trending as investors weigh a potential business combination with Spanish beauty group Puig, a strategic move aimed at achieving greater global scale despite current market headwinds. While some community members view the consolidation as a necessary step to overcome recent performance struggles, others remain cautious due to concerns over potential equity dilution and the company's existing debt profile.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager...

<ul class="summary-bullets"><li>If it materializes, it would be Gilead’s second major acquisition this year after it announced it would buy biotech Arcellx for $7.8 billion last month.</li><li>Ouro Medicine is developing drugs for autoimmune diseases such as lupus and rheumatoid arthritis.&nbsp;</li><li>Gilead is most known for its HIV drug franchise.</li></ul>Gilead Sciences (GILD) is reportedly looking to expand its offerings in the autoimmune disease segment with the acquisition of privately-held biotech Ouro Medicine for up to $2 billion.The Financial Times <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/81528c31-c735-41b7-b042-81a811a76877?syn-25a6b1a6=1">reported</a> on Monday that the company is looking to pay Ouro investors roughly $1.5 billion upfront in cash and at least an extra $500 million if certain clinical trial milestones are hit.As per the report, the talks are at an advanced stage and a deal could be announced in the coming days, though the terms might change. &nbsp;If it materializes, it would be Gilead’s second major acquisition this year after it announced it would buy biotech Arcellx for $7.8 billion last month in order to gain full access to a new multiple myeloma cell therapy.<h2 class="st-heading-2">Gilead’s Acquisition Approach</h2>“...we are carefully strengthening our early-stage pipeline to position Gilead well for the long term, typically investing about $1 billion annually in smaller licensing deals, partnerships, and acquisitions. Additionally, we are proactive and disciplined in our approach to later-stage acquisitions that support our strategic goals and add new growth opportunities,” the company said during its fourth quarter earnings call in February.“We're very ready, we're very proactive and disciplined, but we may not have the urgency of other companies in this sector, so we're gonna be disciplined around that. But I would say that we very much want to continue to add to our pipeline with appropriate, M&amp;A over the course of the coming years as well.”Gilead is most known for its HIV drug franchise. In 2025, the company reported a 6% in HIV product sales to $20.8 billion. The HIV product segment sales accounted for about 72% of the company’s overall product sales in the period.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around GILD stock fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.<a href="https://stocktwits.com/symbol/GILD">GILD stock</a> has gained 29% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-estee-lauder-stock-down-today/cZ3mNcjRIKb">Why Is Estee Lauder Stock Down Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Gilead Sciences logo is displayed on a smartphone screen, with the company's branding visible in the background, on April 20, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Gilead Reportedly Eyes Yet Another Acquisition Worth $2B After Arcellx Deal

The Financial Times reported on Monday that the company is looking to pay Ouro investors roughly $1.5 billion upfront in cash and at least an extra $500 million if certain clinical trial milestones are hit.

Equity

The Financial Times reported on Monday that the company is looking to pay Ouro investors roughly $1.5 billion upfront in cash and at least an extra $500 million if certain clinical trial milestones are hit.


Top Pharmaceutical Stocks Worth Watching - March 23rd

Eli Lilly and Company, AbbVie, Pfizer, Novo Nordisk A/S, Gilead Sciences, Abbott Laboratories, and Insmed are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufact...

Wealth Enhancement Advisory Services LLC Has $77.22 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Wealth Enhancement Advisory Services LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 633,185 share...

Nordea Investment Management AB Increases Position in Gilead Sciences, Inc. $GILD

Nordea Investment Management AB boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC...

New England Research & Management Inc. Buys New Stake in Gilead Sciences, Inc. $GILD

New England Research & Management Inc. bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 11,700 shares of the biopharmaceutical company's stock, v...

Top Pharmaceutical Stocks To Research - March 21st

Abbott Laboratories, AbbVie, Eli Lilly and Company, Bristol Myers Squibb, and Gilead Sciences are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool...

IAM Advisory LLC Takes $1.27 Million Position in Gilead Sciences, Inc. $GILD

IAM Advisory LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund...

BCGM Wealth Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD

BCGM Wealth Management LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 11,746 shares of the biopharmaceutical company's stock, valued at appr...

Confluence Investment Management LLC Trims Stock Position in Gilead Sciences, Inc. $GILD

Confluence Investment Management LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.5% in the 4th quarter, according to its most recent disclosure with the SEC. The...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

GILD
Gilead Sciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GILD News

GILDGilead Sciences, Inc.